Across TCGA pan-cancer cohorts, RASA4CP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RASA4CP data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RASA4CP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASA4CP expression acts as an unfavorable survival marker.
UCEC are the cancer types where RASA4CP Mutation most reproducibly stratifies survival.